Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

por Decaens, Thomas, Barone, Carlo, Assenat, Eric, Wermke, Martin, Fasolo, Angelica, Merle, Philippe, Blanc, Jean-Frédéric, Grando, Véronique, Iacobellis, Angelo, Villa, Erica, Trojan, Joerg, Straub, Josef, Bruns, Rolf, Berghoff, Karin, Scheele, Juergen, Raymond, Eric, Faivre, Sandrine
Publicado 2021

Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

por Decaens, Thomas, Barone, Carlo, Assenat, Eric, Wermke, Martin, Fasolo, Angelica, Merle, Philippe, Blanc, Jean-Frédéric, Grando, Véronique, Iacobellis, Angelo, Villa, Erica, Trojan, Joerg, Straub, Josef, Bruns, Rolf, Berghoff, Karin, Scheele, Juergen, Raymond, Eric, Faivre, Sandrine
Publicado 2021

Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression

por Ryoo, Baek-Yeol, Cheng, Ann-Li, Ren, Zhenggang, Kim, Tae-You, Pan, Hongming, Rau, Kun-Ming, Choi, Hye Jin, Park, Joong-Won, Kim, Jee Hyun, Yen, Chia Jui, Lim, Ho Yeong, Zhou, Dongli, Straub, Josef, Scheele, Juergen, Berghoff, Karin, Qin, Shukui
Publicado 2021